CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients

Heinze, Karolin; Rengsberger, Matthias; Gajda, Mieczyslaw; Jansen, Lars; Osmers, Linea; Oliveira-Ferrer, Leticia; Schmalfeldt, Barbara; Dürst, Matthias; Häfner, Norman; Runnebaum, Ingo B.

doi:10.1186/s13148-021-01006-8

Table 2 Results of univariate LogRank analyses of clinical and molecular variables

From: CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients

Criteria	Status	n	[%]	PFS [month]			OS [month]
Criteria	Status	n	[%]	Median	95% CI	LogRank	Median	95% CI	LogRank
FIGO	I/II	19	10.4	Not reached		*p < 0.001*	145	46.0–244.0	*p = 0.013*
FIGO	III/IV	163	89.6	29	25.5–32.5	*p < 0.001*	62	49.4–74.6	*p = 0.013*
Resection	R0	139	76.8	38	28.3–47.8	*p < 0.001*	78	71.2–84.8	*p < 0.001*
Resection	R1/2	42	23.2	20	13.9–26.1	*p < 0.001*	49	41.2–56.8	*p < 0.001*
Histology	Serous	154	82.8	30	26.6–33.4	p = 0.075	78	34.9–121.1	p = 0.581
Histology	Non-serous	32	17.2	58	0–121.1	p = 0.075	64	54.7–73.3	p = 0.581
Methylation	No marker	77	41.4	30	14.8–45.2	p = 0.147	78	52.5–103.6	p = 0.195
Methylation	≥ 1 marker	109	58.6	31	27.4–34.7	p = 0.147	62	50.1–73.9	p = 0.195
CAMK2N1	U	170	91.4	31	25.2–36.8	*p = 0.021*	74	62.3–85.2	p = 0.06
CAMK2N1	M	16	8.6	16	9.3–22.8	*p = 0.021*	47	31.2–62.8	p = 0.06
ATL1	U	159	85.5	31	25.2–36.8	p = 0.179	64	52.9–75.1	p = 0.273
ATL1	M	27	14.5	27	20.2–33.8	p = 0.179	65	26.6–103.4	p = 0.273
KATNAL2	U	111	59.7	33	23.3–42.1	p = 0.125	78	55.7–100.3	p = 0.161
KATNAL2	M	75	40.3	29	24.6–33.5	p = 0.125	59	52.6–65.4	p = 0.161
KRT86	U	143	76.9	33	25.1–40.9	*p = 0.001*	64	50.1–77.9	p = 0.290
KRT86	M	43	23.1	26	18.1–33.1	*p = 0.001*	73	54.4–91.6	p = 0.290
RUNX3	U	160	86.0	31	26.9–35.1	p = 0.126	73	62.3–83.7	p = 0.179
RUNX3	M	26	14.0	21	4.7–37.2	p = 0.126	55	33.0–77	p = 0.179
CAMK2N1/RUNX3	U	152	81.7	32	26.0–38.0	*p = 0.032*	74	61.7–86.3	*p = 0.045*
CAMK2N1/RUNX3	M	34	18.3	21	3.8–38.1	*p = 0.032*	57	43.6–70.4	*p = 0.045*
CAMK2N1/KRT86	U	133	71.5	37	25.9–48.1	*p < 0.001*	74	58.0–90.0	p = 0.128
CAMK2N1/KRT86	M	53	28.5	26	18.5–32.8	*p < 0.001*	60	42.9–77.1	p = 0.128
CAMK2N1/KRT86/RUNX3	U	123	66.1	37	19.2–54.8	*p = 0.001*	74	57.0–91.0	p = 0.106
CAMK2N1/KRT86/RUNX3	M	63	33.9	29	23.0–35.0	*p = 0.001*	60	43.1–76.9	p = 0.106
BRCA1	U	166	89.7	31	27.2–34.8	p = 0.626	73	61.4–84.6	p = 0.308
BRCA1	M	19	10.3	25	11.8–37.4	p = 0.626	57	43.8–70.2	p = 0.308

LogRank results with significance are marked in bold. U, unmethylated; M, methylated. Marker combinations are positive (methylated) if at least one single marker is methylated (<OR> combinations) otherwise the combination is scored as unmethylated

Back to article page

ISSN: 1868-7083

Contact us

Submission enquiries: avalyn.villar@springernature.com
General enquiries: info@biomedcentral.com

Clinical Epigenetics

Contact us